AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Bonesupport Holding

Board/Management Information Dec 18, 2019

3016_rns_2019-12-18_4bac73b8-705f-4211-9731-9c574f9eee86.pdf

Board/Management Information

Open in Viewer

Opens in native device viewer

Press Release

BONESUPPORT appoints Kristina Ingvar to Executive Vice President Quality Management & Regulatory Affairs

Lund, Sweden, 15:00 CET, 18 December 2019 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, announces changes in its leadership team. Kristina Ingvar starts with the company February 1, 2020 and will formally take on the position as the Executive Vice President Quality Management & Regulatory Affairs of the company from 1 April 2020, in connection with Carin Nilsson-Thorell's retirement. Kristina has a medical degree from Lund University. She joins BONESUPPORT from Novo Nordisk, where her most recent role has been Global Program Vice President, Regulatory Affairs. During her 20-year long career Kristina has held various product, project and people management positions in the regulatory, quality, safety and medical areas. Kristina has worked closely with R&D and Manufacturing & Supply, as well as Sales & Marketing in both small and large companies.

"Kristina Ingvar is the right person to take on the responsibility for our regulatory and quality functions. Kristina's experience in the field, together with her leadership and marketoriented thinking will be of great value to us. At the same time, I would like to extend a big thank you to Carin Nilsson-Thorell who has meant a lot to the company and its journey for many years and wish her all the best for the future" says Emil Billbäck, BONESUPPORT's CEO.

About BONESUPPORT™

BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2021. The company is based in Lund, Sweden, and the net sales amounted to SEK 97 million in 2018. Please visit www.bonesupport.com for more information.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

For more information contact:

BONESUPPORT AB

Emil Billbäck, CEO +46 (0) 46 286 53 70

Håkan Johansson, CFO +46 (0) 46 286 53 70 [email protected]

Press Release

Cord Communications

Charlotte Stjerngren +46 (0)708 76 87 87 [email protected] www.cordcom.se

Talk to a Data Expert

Have a question? We'll get back to you promptly.